Javier Cortés
哈维尔·科尔特斯
MD, PhD
Director, IOB Institute of Oncology Madrid马德里IOB肿瘤学研究所主任
👥Biography 个人简介
Professor Javier Cortés is one of Europe's most prolific breast cancer trialists. He led the KEYNOTE-522 trial establishing pembrolizumab in early triple-negative breast cancer and spearheaded landmark T-DXd and T-DM1 trials, reshaping HER2-positive breast cancer treatment globally.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
HER2-Targeted Antibody-Drug Conjugates
Led and contributed to pivotal trials of trastuzumab deruxtecan (T-DXd) including DESTINY-Breast01/02/03/04, establishing T-DXd as preferred HER2+ and HER2-low second-line therapy.
Immunotherapy in Triple-Negative Breast Cancer
Coordinated KEYNOTE-522 in early TNBC, demonstrating pembrolizumab plus chemotherapy significantly improved pathological complete response and event-free survival, establishing a new standard of care.
Eribulin and Novel Agents in Pretreated Breast Cancer
Contributed to pivotal EMBRACE trial supporting eribulin approval in heavily pretreated metastatic breast cancer, and led early-phase evaluation of numerous novel breast cancer agents.
Representative Works 代表性著作
Pembrolizumab for Early Triple-Negative Breast Cancer
New England Journal of Medicine (2020)
KEYNOTE-522: established pembrolizumab + chemotherapy as neoadjuvant/adjuvant standard of care in early TNBC with significantly improved pCR and EFS.
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for HER2-Positive Metastatic Breast Cancer
New England Journal of Medicine (2022)
DESTINY-Breast03: T-DXd demonstrated markedly superior PFS over T-DM1, establishing it as the preferred second-line HER2+ metastatic breast cancer therapy worldwide.
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
New England Journal of Medicine (2022)
DESTINY-Breast04: T-DXd provided superior survival benefit in HER2-low breast cancer, defining a new targetable population and expanding ADC indications significantly.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
关注 哈维尔·科尔特斯 的研究动态
Follow Javier Cortés's research updates
留下邮箱，当我们发布与 Javier Cortés（IOB Institute of Oncology, Madrid / Vall d'Hebron Barcelona）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment